Compare MDBH & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | KYNB |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 31.9M |
| IPO Year | 2022 | N/A |
| Metric | MDBH | KYNB |
|---|---|---|
| Price | $3.10 | $8.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 31.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.06 | ★ $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.00 | $7.11 |
| 52 Week High | $7.20 | $9.58 |
| Indicator | MDBH | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 49.31 |
| Support Level | N/A | $7.37 |
| Resistance Level | $3.84 | $8.88 |
| Average True Range (ATR) | 0.11 | 0.62 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 33.90 | 57.18 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.